Clinical relevance of plasma ADAM-17 with cognition and neurodegeneration in Alzheimer's disease
Zu-Qi Chen, Meng-Ting Wang, Cheng-Rong Tan, Shan Huang, Fa-Ying Zhou, Ying-Ying Shen, Gui-Hua Zeng, Dong-Yu Fan, Yan-Jiang WangBackground
A disintegrin and metalloproteinase 17 (ADAM-17) has multiple pathophysiological functions in Alzheimer's disease (AD). However, the clinical relevance of ADAM-17 in AD is not clear yet.
Objective
This study aims to investigate the levels of circulating ADAM-17 and their association with AD.
Methods
This cross-sectional study recruited 40 normal cognition (NC) participants and 36 AD patients. Plasma ADAM-17 and biomarkers of neurodegeneration were determined. The association of plasma ADAM-17 with cognitive functions and biomarkers of neurodegeneration was analyzed.
Results
Plasma ADAM-17 levels were elevated in AD patients in comparison with NC subjects. Plasma ADAM-17 was positively associated with Clinical Dementia Rating (CDR) scores, but negatively associated with the Mini-Mental State Examination scores and Montreal Cognitive Assessment scores. Plasma ADAM-17 levels were positively associated with the levels of Aβ40, Aβ42, and p-Tau181.
Conclusions
These findings suggest a link between ADAM-17 and the pathogenesis of AD from a clinical perspective.